Toxoplasmosis Risk Assessment (Congenital and Immunocompromised)
Assesses risk of active or congenital toxoplasmosis. Guides spiramycin/pyrimethamine-sulphadiazine therapy and neonatal screening.
Score interpretation
→ Reassurance; general hygiene advice (cook meat thoroughly, avoid cat litter); rescreen in pregnancy at 36 weeks if initially negative; no treatment needed for past infection in immunocompetent
→ Avidity testing to confirm acute vs chronic infection; MRI brain if immunocompromised (ring-enhancing lesions); PCR of blood/CSF if CNS disease suspected; ID/obstetric input; spiramycin in first trimester pregnancy
→ Pyrimethamine 200mg load then 75mg/day + sulphadiazine 4g/day + folinic acid 15mg/day x 6 weeks (CNS disease in HIV); congenital: neonatal treatment 12 months; ophthalmology for ocular toxoplasmosis; ID specialist mandatory
Interpretation bands for the Toxoplasmosis Risk. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Hydroxycarbamide (Hydroxyurea) · Cytotoxic / Disease-Modifying Agent
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.